Company Overview and News

 
S&P/ASX 200 closes up 35 points as investors recover a bit of poise

2018-02-13 proactiveinvestors.com.au
National Australia Bank's business confidence index jumped 6 points to 19 points in January, which is materially above the long-run average of 5 points.

 
S&P/ASX 200 gains ground with miners advancing

2018-02-13 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX:XJO) is trading 0.42% up at 5845, with BHP Billiton (ASX:BHP) rising 1.1% and Rio Tinto (ASX:RIO) shares up 1.7%.

 
S&P/ASX 200 opens flat, investors sell results from Boral, Challenger and Cochlear

2018-02-13 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX: XJO) (ASX:XJO) opened flat this morning at 5,820.7 defying expectations of a strong open.

 
Cochlear Limited Introduces The World's First Made For iPhone Cochlear Implant Sound Processor

2017-07-26 devicespace
CENTENNIAL, Colo., July 26, 2017 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces today its latest innovation, the Cochlear Nucleus® 7 Sound Processor. Approved by the U.S. Food and Drug Administration (FDA) in June, the Nucleus 7 Sound Processor is the world's first Made for iPhone cochlear implant sound processor and the smallest and lightest behind-the-ear cochlear implant sound processor available on the market.

 
Coach (COH) Beats on Q1 Earnings, Keeps Guidance Intact

2016-11-01 zacks
Despite a tough retail environment, volatility in tourist spending and macroeconomic headwinds, Coach, Inc. (COH - Analyst Report) posted better-than-expected first-quarter fiscal 2017 bottom-line results. The company's adjusted earnings of 45 cents a share beat the Zacks Consensus Estimate by a penny, thereby resulting in a positive earnings surprise of 2.3% and marking the 11th straight quarter of earnings beat.

 
Coach (COH) Q1 Earnings Top, Revenues Miss Estimates

2016-11-01 zacks
Coach Inc. (COH - Analyst Report) , the designer handbag maker, came out with first-quarter fiscal 2017 results, wherein adjusted earnings of 45 cents surpassed the Zacks Consensus Estimate by a penny and also increased 9.8% year over year. For fiscal 2017, the company continues to expect double-digit growth in both net income and earnings. Earnings Estimate Revision: The Zacks Consensus Estimate for fiscal 2017 has been stable over the past 30 days.

 
Apparel Stocks' Earnings Scheduled for Nov 1: COH, SHOO

2016-10-31 zacks
The earnings growth scenario in Q3 is pretty clear as we step into the second half of the reporting cycle. Also, the quarter has been persistently heading toward an improvement after five straight quarters of earnings decline. This period is a significant one with both earnings and revenues on the growth trajectory. Per our Earnings Preview report as of Oct 28, out of the 291 S&P 500 companies that have come up with their quarterly numbers, approximately 73.

 
Admedus Ltd appoints new CFO as part of move to Brisbane

2016-08-26 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has appointed Mark Ziirsen as chief financial officer as the company relocates its corporate services functions to Brisbane. Ziirsen joins Admedus from Cochlear Ltd (ASX:COH), where he held the role of director of finance and I.T. for Asia Pacific for the past five years. Wayne Paterson, interim CEO, commented: “Today’s announcement is regarded as both a significant and essential development for Admedus as we scale our business to meet the demands of all of Admedus’ stakeholders.

 
Becoming a substantial holder

2016-05-13 asx.com.au

 
Appendix 3B

2016-04-14 asx.com.au

 
Cochlear Limited Release: New Online Resource Available To Help Parents Of A Child With Hearing Loss

2016-04-04 devicespace
CENTENNIAL, Colo., April 4, 2016 /PRNewswire/ -- One to six in 1,000 children in the United States are born with severe to profound hearing loss.1 For a parent, that diagnosis can be life altering, and they are in need of help, information and support. Today, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces IWantYouToHear.com as part of its ongoing commitment to parents seeking treatment options for their child's severe to profound hearing loss.

 
New online resource available to help parents of a child with hearing loss

2016-04-04 prnewswire
CENTENNIAL, Colo., April 4, 2016 /PRNewswire/ -- One to six in 1,000 children in the United States are born with severe to profound hearing loss.1 For a parent, that diagnosis can be life altering, and they are in need of help, information and support. Today, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces IWantYouToHear.com as part of its ongoing commitment to parents seeking treatment options for their child's severe to profound hearing loss.

 
Appendix 3Y - Rick Holliday-Smith

2016-04-01 asx.com.au

 
Half Year Report 2016

2016-03-31 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...